Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus chemoradiotherapy in muscle-invasive bladder cancer
NCT03993249Phase 2Unknown
- Sponsor
- Hellenic Genito-Urinary Cancer Group
- Start
- May 2019
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in bladder cancer, sponsored by Hellenic Genito-Urinary Cancer Group. Status: unknown.
02
Drugs
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT03993249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03993249.